{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:54:11Z","timestamp":1790729651167,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:00:00Z","timestamp":1385078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Discrepancies exist for some of the modified coagulation factors when assayed with different one\u2010stage clotting and chromogenic substrate assay reagents. The aim of this study was to evaluate the performance of a recombinant factor VIII Fc fusion protein (rFVIIIFc), currently in clinical development for the treatment of severe haemophilia A, in a variety of one\u2010stage clotting and chromogenic substrate assays in clinical haemostasis laboratories. Haemophilic plasma samples spiked with rFVIIIFc or Advate<jats:sup>\u00ae<\/jats:sup> at 0.05, 0.20 or 0.80\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup> were tested by 30 laboratories using their routine procedures and plasma standards. Data were evaluated for intra\u2010 and inter\u2010laboratory variation, accuracy and possible rFVIIIFc\u2010specific assay discrepancies. For the one\u2010stage assay, mean recovery was 95% to 100% of expected for both Advate<jats:sup>\u00ae<\/jats:sup> and rFVIIIFc at 0.8\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup>. Intra\u2010laboratory percent coefficient of variance (<jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>) ranged from 6.3% to 7.8% for Advate<jats:sup>\u00ae<\/jats:sup>, and 6.0% to 10.3% for rFVIIIFc. Inter\u2010laboratory <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content> ranged from 10% for Advate<jats:sup>\u00ae<\/jats:sup> and 16% for rFVIIIFc at 0.8\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup>, to over 30% at 0.05\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup> for both products. For the chromogenic substrate assay, the average FVIII recovery was 107%\u00a0\u00b1\u00a05% and 124%\u00a0\u00b1\u00a08% of label potency across the three concentrations of Advate<jats:sup>\u00ae<\/jats:sup> and rFVIIIFc, respectively. Plasma rFVIIIFc levels can be monitored by either the one\u2010stage or the chromogenic substrate assay routinely performed in clinical laboratories without the need for a product\u2010specific rFVIIIFc laboratory standard. Accuracy by the one\u2010stage assay was comparable to that of Advate<jats:sup>\u00ae<\/jats:sup>, while marginally higher results may be observed for rFVIIIFc when using the chromogenic assay.<\/jats:p>","DOI":"10.1111\/hae.12296","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T06:51:25Z","timestamp":1385189485000},"page":"294-300","source":"Crossref","is-referenced-by-count":78,"title":["Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories"],"prefix":"10.1111","volume":"20","author":[{"given":"J. M.","family":"Sommer","sequence":"first","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Moore","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"McGuffie\u2010Valentine","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bardan","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Buyue","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Kamphaus","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A.","family":"Konkle","sequence":"additional","affiliation":[{"name":"Puget Sound Blood Center Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. F.","family":"Pierce","sequence":"additional","affiliation":[{"name":"Biogen Idec Hemophilia Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S6885"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440641.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02481.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00657.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-32658"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.3406_1.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440646.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00481.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02523.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.01983.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02789.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649687"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02831.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01880.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-367813"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.739"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"e_1_2_8_20_1","first-page":"PO104","article-title":"Phase 3 Clinical Study of Recombinant Fc Fusion Factor FVIII (rFVIIIFc) Demonstrated Safety, Efficacy, and Improved Pharmacokinetics (A\u2010LONG)","volume":"19","author":"Mahlangu J","year":"2013","journal-title":"Haemophilia"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12076"},{"key":"e_1_2_8_22_1","first-page":"131","article-title":"Assay discrepancies with highly purified factor VIII concentrates","volume":"19","author":"Dawson NJ","year":"1989","journal-title":"Haemostasis"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01715.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02333.x"},{"key":"e_1_2_8_25_1","volume-title":"Advate Prescribing Information","year":"2012"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12296","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.12296","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:27:28Z","timestamp":1695569248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/hae.12296"],"URL":"https:\/\/doi.org\/10.1111\/hae.12296","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}